DALE MICHAEL D - 18 Feb 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: SENIOR VICE PRESIDENT
Signature: /s/ Michael D. Dale by Jessica H. Paik, Attorney-in-Fact
Issuer symbol: ABT
Transactions as of: 18 Feb 2022
Transactions value $: $0
Form type: 4
Filing time: 23 Feb 2022, 19:06:08 UTC
Previous filing: 30 Jul 2021
Next filing: 02 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+11,647	+29.34%	$0	51,338	18 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+54,280		$0	54,280	18 Feb 2022	Common Shares	54,280	$117.58	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025.